ES2771675T3 - Nuevas cepas recombinantes de Bordetella - Google Patents

Nuevas cepas recombinantes de Bordetella Download PDF

Info

Publication number
ES2771675T3
ES2771675T3 ES18194351T ES18194351T ES2771675T3 ES 2771675 T3 ES2771675 T3 ES 2771675T3 ES 18194351 T ES18194351 T ES 18194351T ES 18194351 T ES18194351 T ES 18194351T ES 2771675 T3 ES2771675 T3 ES 2771675T3
Authority
ES
Spain
Prior art keywords
protein
fha
strain
fragment
bordetella pertussis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18194351T
Other languages
English (en)
Spanish (es)
Inventor
Camille Locht
Nathalie Mielcarek
Hana Kammoun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur de Lille
Institut National de la Sante et de la Recherche Medicale INSERM
Institut Pasteur
Universite de Lille
Original Assignee
Institut Pasteur de Lille
Institut National de la Sante et de la Recherche Medicale INSERM
Institut Pasteur
Universite de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur de Lille, Institut National de la Sante et de la Recherche Medicale INSERM, Institut Pasteur, Universite de Lille filed Critical Institut Pasteur de Lille
Application granted granted Critical
Publication of ES2771675T3 publication Critical patent/ES2771675T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
ES18194351T 2012-10-17 2013-10-17 Nuevas cepas recombinantes de Bordetella Active ES2771675T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12306279.6A EP2722338A1 (en) 2012-10-17 2012-10-17 Novel recombinant Bordetella strains

Publications (1)

Publication Number Publication Date
ES2771675T3 true ES2771675T3 (es) 2020-07-06

Family

ID=47073385

Family Applications (2)

Application Number Title Priority Date Filing Date
ES18194351T Active ES2771675T3 (es) 2012-10-17 2013-10-17 Nuevas cepas recombinantes de Bordetella
ES13777082T Active ES2715651T3 (es) 2012-10-17 2013-10-17 Nuevas cepas de Bordetella recombinantes

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES13777082T Active ES2715651T3 (es) 2012-10-17 2013-10-17 Nuevas cepas de Bordetella recombinantes

Country Status (10)

Country Link
US (1) US9528086B2 (https=)
EP (3) EP2722338A1 (https=)
JP (3) JP6473086B2 (https=)
CN (2) CN110923181A (https=)
AU (1) AU2013333928B2 (https=)
CA (1) CA2887055C (https=)
DK (2) DK2909229T3 (https=)
ES (2) ES2771675T3 (https=)
SG (2) SG10201706392YA (https=)
WO (1) WO2014060514A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3800244A1 (en) 2006-03-10 2021-04-07 Institut Pasteur de Lille Live attenuated bordetella strains as a single dose vaccine against whooping cough
CA2759280C (en) 2009-04-28 2016-09-20 Inserm (Institut National De La Sante Et De La Recherche Medicale) Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
CN104302314B (zh) 2011-11-02 2020-06-02 新加坡国立大学 减毒博代氏杆菌菌株对抗变应性疾病的效果
EP2722338A1 (en) 2012-10-17 2014-04-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel recombinant Bordetella strains
KR101672719B1 (ko) * 2014-07-22 2016-11-04 전남대학교산학협력단 바이러스 중화항원 단백질 발현을 위한 보르데텔라 백일해 균주 및 이를 이용한 면역원성 조성물
US9655959B2 (en) 2014-10-01 2017-05-23 National University Of Singapore Adenylate cyclase deficient bordetella strains
EP3283102A4 (en) 2015-04-16 2018-10-03 Inventprise, LLC. Bordetella pertussis immunogenic vaccine compositions
CN109069535B (zh) 2016-03-29 2022-03-18 里尔巴斯德研究所 突变型博德特氏菌属菌株及其使用方法
CA3077428A1 (en) 2017-10-18 2019-04-25 Institut Pasteur De Lille Bordetella strains expressing serotype 3 fimbriae
JP2022520925A (ja) * 2019-01-04 2022-04-04 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド 弱毒化ボルデテラ・ブロンキセプチカ株、当該弱毒化株を含む経口ワクチン並びに前記の製造及び使用方法
CN116322756A (zh) 2020-08-14 2023-06-23 伊利亚特生物技术有限责任公司 经冻干的活鲍特菌属疫苗
EP3909971A1 (en) 2020-09-28 2021-11-17 Institute of Life Sciences (ILS) Whole cell livestock vaccine for respiratory diseases
EP4247397A4 (en) * 2020-11-17 2024-11-06 Iliad Biotechnologies, LLC TREATMENT AND PREVENTION OF NEUROPATHOLOGY ASSOCIATED WITH NEURODEGENERATIVE DISEASES
CN113429188B (zh) * 2021-06-18 2022-06-10 湖北沛高环保科技有限公司 一种尾矿固废综合处理利用方法
CN116265584A (zh) * 2021-12-17 2023-06-20 远大赛威信生命科学(南京)有限公司 百日咳抗原重组表达载体及其工程菌和应用
WO2025257397A1 (en) * 2024-06-14 2025-12-18 Institut National de la Santé et de la Recherche Médicale Live attenuated bordetella vaccines capable of producing and secreting heterologous antigens
CN118853525B (zh) * 2024-09-26 2025-01-07 上海羽冠生物技术有限公司 经修饰的百日咳鲍特菌菌株

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713072B1 (en) 1987-11-02 2004-03-30 Chiron S.R.L. Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine
GB9115332D0 (en) * 1991-07-16 1991-08-28 Connaught Lab Manipulation of gene copy number in bordetella
FR2718750B1 (fr) * 1994-04-19 1996-06-14 Pasteur Institut Protéines recombinantes de l'hémagglutinine filamenteuse de Bordetella, notamment, B. Pertussis, production et application à la production de protéines étrangères ou de principes actifs vaccinants.
FR2728170A1 (fr) * 1994-12-15 1996-06-21 Pasteur Institut Vaccin de type acellulaire anti-bordetella
FR2754543B1 (fr) 1996-10-11 1998-12-31 Pasteur Institut Souche de bordetella deficiente dans la production de toxine et exprimant une proteine hydride, liposomes comprenant de la fha et leurs utilisations comme vaccins, et utilisation de la fha pour stimuler les reponses immunitaires
FR2840319B1 (fr) 2002-05-30 2004-08-20 Pasteur Institut Souches de bordetella rendues deficientes par attenuation genetique
CA2522007A1 (en) 2003-04-11 2004-10-28 Medimmune, Inc. Methods of preventing or treating respiratory conditions
EP3800244A1 (en) 2006-03-10 2021-04-07 Institut Pasteur de Lille Live attenuated bordetella strains as a single dose vaccine against whooping cough
DK2069503T3 (da) 2006-11-15 2016-02-15 Folia Biotech Inc Papayamosaikvirus-baserede vacciner mod influenza
CA2690641A1 (en) 2007-06-18 2008-12-24 Hemispherx Biopharma, Inc. Early intervention of viral infections with immune activators
JP2011116659A (ja) * 2008-03-13 2011-06-16 Chemo-Sero-Therapeutic Research Inst 組換え皮膚壊死トキソイドを含有する豚萎縮性鼻炎用薬剤
CA2759280C (en) 2009-04-28 2016-09-20 Inserm (Institut National De La Sante Et De La Recherche Medicale) Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
WO2010146414A1 (en) 2009-06-15 2010-12-23 National University Of Singapore Influenza vaccine, composition, and methods of use
CN104302314B (zh) 2011-11-02 2020-06-02 新加坡国立大学 减毒博代氏杆菌菌株对抗变应性疾病的效果
EP2722338A1 (en) 2012-10-17 2014-04-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel recombinant Bordetella strains

Also Published As

Publication number Publication date
DK3459966T3 (da) 2020-02-17
EP3459966B1 (en) 2019-11-27
AU2013333928B2 (en) 2017-11-30
US20150210978A1 (en) 2015-07-30
AU2013333928A1 (en) 2015-04-09
EP3459966A1 (en) 2019-03-27
EP2909229A1 (en) 2015-08-26
ES2715651T3 (es) 2019-06-05
CN110923181A (zh) 2020-03-27
CN104936976B (zh) 2019-11-22
CN104936976A (zh) 2015-09-23
DK2909229T3 (en) 2019-03-25
JP2019088303A (ja) 2019-06-13
JP7277516B2 (ja) 2023-05-19
WO2014060514A1 (en) 2014-04-24
EP2909229B1 (en) 2018-12-12
US9528086B2 (en) 2016-12-27
SG11201502010TA (en) 2015-04-29
JP6473086B2 (ja) 2019-02-20
SG10201706392YA (en) 2017-09-28
HK1213926A1 (en) 2016-07-15
EP2722338A1 (en) 2014-04-23
CA2887055A1 (en) 2014-04-24
JP6914976B2 (ja) 2021-08-04
CA2887055C (en) 2023-03-21
JP2021164481A (ja) 2021-10-14
JP2015536134A (ja) 2015-12-21

Similar Documents

Publication Publication Date Title
ES2771675T3 (es) Nuevas cepas recombinantes de Bordetella
ES2821830T3 (es) Cepas de Bordetella vivas atenuadas como vacuna de dosis única contra la tos ferina
JP4673974B2 (ja) アジュバントとしての変異コレラホロトキシン
JP7812352B2 (ja) 血清型３線毛を発現するボルデテラ（ｂｏｒｄｅｔｅｌｌａ）菌株
Ho et al. Highly attenuated Bordetella pertussis strain BPZE1 as a potential live vehicle for delivery of heterologous vaccine candidates
Li et al. Development of live attenuated Bordetella pertussis strains expressing the universal influenza vaccine candidate M2e
HK40003310B (en) Novel recombinant bordetella strains
HK40003310A (en) Novel recombinant bordetella strains
HK1213926B (en) Novel recombinant bordetella strains
CN101400783B9 (zh) 包特氏菌减毒活菌株作为抗百日咳的单剂量疫苗
Matsui Salmonella Flagellin Is Not a Dominant Protective Antigen in Oral Immunization with Attenuated Live Vaccine Strains
WO2025257397A1 (en) Live attenuated bordetella vaccines capable of producing and secreting heterologous antigens
Guzmàn et al. Use of Salmonella Spp. Carrier Strains to Deliver Bordetella Pertussis Antigens in Mice using the oral Route
Locht et al. Bordetella pertussis Highly Attenuated